Parsaclisib is currently under evaluation in combination with the anti-CD19 monoclonal antibody tafasitamab in patients with RR CLL and RR NHL as part of a phase 1/2 study (#NCT04809467). The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.